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  BACKGROUND: The association between epicardial fat and coronary in-stent restenosis has 
not been evaluated. The objective of the present study was to evaluate the relationship of 
echocardiographic epicardial fat thickness (EFT) with restenosis in drug eluting stents (DES). 
 METHODS:  In this study, 117 patients who underwent coronary angiography due to recurrent 
clinical symptoms or findings of non-invasive cardiac tests one year after stent implantation 
were selected. According to angiographic results, they were divided into two groups, 65 patients 
with in-stent restenosis (case group) and 52 patients without such finding (control group). EFT 
was measured perpendicularly on the free wall of the right ventricle at the end of systole in two 
echocardiographic views (parasternal short and long axis) at least in three cardiac cycles. The 
average of obtained values was determined and recorded as EFT. Furthermore, the history of 
hypertension, smoking and diabetes, age and sex were investigated and body mass index (BMI) 
of each patient was also calculated. 
 RESULTS: There were no significant differences in the baseline characteristics (P = 0.812). 
Patients with in-stent restenosis did not have statistically significant difference (4.6 ± 1.8 mm) 
in EFT compared to subjects with patent stents (4.5 ± 1.8 mm; P = 0.88). The above results were 
also confirmed using multiple linear regressions. No significant correlation was found between 
EFT and other clinical variables (P > 0.05). 
  CONCLUSION: In this selected population, the risk of restenosis was not correlated with 
epicardial fat thickness. Future studies for determining the role of epicardial fat in development 
of in-stent restenosis are warranted. 
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Introduction 
Development of intracoronary stents has profoundly 
influenced interventional cardiology. Coronary stents 
have emerged as the predominant form of 
percutaneous coronary intervention (PCI)  and  are 
currently used in more than 90 percent of PCI 
procedures worldwide.1 
  Although metallic stents conferred a significant 
advantage over balloon angioplasty both in reducing 
initial complications (such as abrupt vessel closure, 
emergency coronary artery bypass graft) and 
improving late clinical outcomes (by reducing rate of 
  (BMS) placement restenosis remained a major 
obstacle due to wider application of percutaneous 
revascularization especially in complex lesions.2 
  While bare metal coronary stents reduce the 
incidence of angiographic and clinical restenosis 
compared to balloon angioplasty, angiographic 
restenosis (follow-up diameter stenosis > 50 percent) 
still occurs in 20 to 30% of patients and clinical 
restenosis (recurrent angina due to restenosis in the 
treated coronary segment) develops in 10 to 15 
percent of patients in the first year after treatment.3,4  
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Excessive intimal hyperplasia with smooth muscle 
proliferation within the stent is the key mechanism of 
restenosis after coronary stent implantation.2 
  In-stent restenosis (ISR) has developed into a 
significant clinical problem, and is responsible for a 
large proportion of repeated PCI procedures. Among 
unselected patients undergoing PCI, repeated 
revascularization occurs in 14% and increases 1-year 
healthcare costs by > $19 000 per occurrence. These 
findings have important implications for the cost 
effectiveness of new treatments that substantially 
reduce in-stent restenosis.5  
  The most exciting strategy for restenosis 
prevention has been the drug-eluting stents 
scaffolding with local pharmacologic action.6,7 The 
use of drug-eluting stents (DES) has lowered the 
incidence of ISR further, with clinical restenosis 
rates less than 10% in contemporary practice.7 
  Restenosis with drug eluting stents (DES) occurs 
more often in patients with history of restenosis or 
diabetes mellitus, small vessels (reference 
vessel diameter < 2.5mm), long lesions (lesion length 
> 20mm), chronic total occlusions and saphenous 
vein grafts.1 We searched the Cochrane Library, 
EMBASE, and Medline databases through June 2010 
for studies investigating the association of epicardial 
fat and in-stent restenosis but did not find any article 
for such correlation.  
 
Mechanisms of in-stent Restenosis 
It is hypothesized that restenosis is a manifestation of 
the general wound healing response expressed 
specifically in vascular tissue. The temporal response 
to injury occurs in three characteristic phases: 
inflammation, granulation, and extracellular matrix 
remodeling. The specific expression of these phases 
in the coronary artery leads to intimal hyperplasia at 1 
to 4 months.8  The central role of autocrine and 
paracrine inflammatory mediators on smooth muscle 
proliferation at the site of vascular injury has been 
proposed.9 
  In the normal adults, epicardial fat is concentrated 
in the atrioventricular (AV) and interventricular (IV) 
grooves and along the major branches of the coronary 
arteries, and to a lesser extent, around the atria, over 
the free wall of the right ventricle (RV) and over the 
apex of the left ventricle (LV).10-12 However, fairly 
little is known about its physiologic and metabolic 
roles. A body of evidence shows that epicardial fat is 
an extremely active organ with various endocrine and 
paracrine functions, It is a source of several 
proinflammatory and proatherogenic cytokines 
(tumor necrosis factor-, monocyte chemoattractant 
protein-1, interlukin-6, nerve growth factor, resistin, 
visfatin, omentin, leptin, plasminogen activator 
inhibitor-1, and angiotensinogen).13-18 By synthesizing 
and releasing these mediators, epicardial fat might 
implicated in the development of epicardial coronary 
atherosclerosis.19-21 Lack of any fascia between the 
adipocytes and myocardium allows direct interaction 
of vascular bed and the surrounding epicardial fat.11 
In other words, no muscle fascia divides epicardial fat 
and myocardium, therefore, the two tissues share the 
same microcirculation. Secretion of adipokines out of 
adipocytes and diffusion into the coronary arteries has 
been demonstrated.22 
  In the vasculature, inflammatory signals are usually 
linked to blood-borne cells (e.g. macrophages and T 
cells) retained in the intima and activated resident 
cells of vascular origin.13 Interestingly, inflammatory 
mediators originating outside the coronary arteries are 
also capable of inducing compositional changes in the 
inner layer of intima.23,24 There is growing evidence 
that the changes in or perivascular tissue surrounding 
epicardial coronary arteries could alter vascular 
homeostasis and contribute to endothelial 
dysfunction, amplification of vascular inflammation, 
intimal lesions, plaque progression by an “outside-to-
inside” signaling mechanism. By the concept of such 
“outside-to-inside” cellular cross talk, inflammatory 
mediators outside the coronary artery, such as 
epicardial and adventitial inflammation, may 
contribute to intimal atherosclerotic lesions.23-26  In 
addition, some recent studies demonstrated 
augmented inflammatory responses, as reflected by 
the presence of several inflammatory mediators and 
inflammatory cell infiltrates, in subepicardial adipose 
tissue in patients with significant CAD.13,27  
  In this context, and on the basis of these 
pathophysiologic and clinical data, we suppose that 
the presence of metabolically active adipose stores 
that surround epicardial coronary arteries (epicardial 
fat) could intensify and contribute to the 
inflammatory burden at the site of vascular injury by 
stenting. The potential role of epicardial fat in the 
development of in-stent restenosis could be an 
attractive hypothesis and is the basis for our study. 
The association between subepicardial adipose tissue 
and epicardial CAD has not been evaluated. As far as 
we know, this is the first study to address the 
potential association between subepicardial adipose 
tissue and development de-novo intracoronary lesions 
at the site of stent deployment (in-stent restenosis) 
  The size of this metabolically active tissue (which 
could act as important source of inflammatory 
mediators) can be measured by magnetic resonance 
imaging (MRI), computed tomography and trans-
thoracic echocardiography. MRI and CT scan are 
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certainly precise, but they are expensive and 
cumbersome in clinical practice.28  Epicardial fat 
thickness (EFT) can be visualized and measured with 
two-dimensional (2D) echocardiography as first 
proposed and validated by Iacobellis et al.29,30 
Transthoracic echocardiography provides a reliable 
measurement of epicardial adipose tissue thickness 
and has been validated with MRI, one of the widely 
accepted reference standards to measure visceral 
adiposity.29 Echocardiographic epicardial fat 
measurement in both clinical and research scenarios 
has several advantages, including its low cost, easy 
accessibility, rapid applicability, and good 
reproducibility. Thus, the present study was designed 
to assess the association between epicardial fat 
measured by trans-thoracic echocardiography and the 
development of in-stent restenosis. 
Materials and Methods 
Study population 
We studied patients who underwent coronary 
angiography at least 12 month after drug eluting stent 
(DES) implantation, as clinically indicated at the 
discretion of the referring cardiologist. This case-
control study was conducted from January to May 
2010 in the department of heart diseases of Chamran 
hospital in Isfahan, Iran (referral hospital, affiliates to 
Isfahan University of Medical Sciences). Patients with 
confirmed in-stent restenosis by angiography (case 
group) and persons with patent stent in angiography 
(control group) enrolled in the study.  
  Exclusion criteria included poor echo images, 
difficulties in differentiating epicardial, mediastinal 
and pericardial fat as well as pericardial effusion and 
history of in-stent restenosis. All participants were 
given informed written consent prior to the study, 
which was performed in accordance with the ethical 
standards of the 1964 Declaration of Helsinki as 
revised in 2000. 
  After registering demographic data such as age, 
sex, weight and height, history of diabetes mellitus, 
smoking and hypertension, size and name of stent 
and coronary artery which stent was deployed, 
subjects underwent trans-thoracic echocardiography 
(vivid3, GE, USA). EFT was measured with standard 
technique in short and long axis views. The mean of 
EFT was compared between groups as a primary end 
point. The association of epicardial fat thickness with 
age and obesity (BMI < 30) was the secondary end 
points. 
  Height and weight were measured by using 
standardized procedures at both surveys, and we 
computed body mass index (BMI) as weight in 
kilogram divided by the square of height (m2). 
Hypertension was defined as systolic blood   
pressure  ≥ 140 mmHg, or diastolic blood   
pressure  ≥ 90 mmHg, or requirement for 
antihypertensive medication. Diabetes mellitus was 
defined according to the criteria of the American 
Diabetes Association, or requirement for insulin or 
oral hypoglycemic drugs.31 
 
Coronary angiographic data 
Angiographic restenosis was defined as diameter 
stenosis ≥ 50% by quantitative coronary angiography 
(QCA) in the stent and in the stented segment 
(defined as the stent plus the 5mm edges proximal 
and distal to the stent) during diastole. In the cases 
that overlapping stents were placed, a single in-stent 
value was measured and the segment was considered 
as the entirely stented segment plus the 5mm 
proximal to the more proximal stent and the 5mm 
distal to the more distal stent implanted. Coronary 
arteries were visualized at least in two orthogonal 




 A-Technical  tips: 
Epicardial fat was identified as an echo-free space in 
the pericardial layers on the 2-dimensional 
echocardiography (Figure 1). Mediastinal fat presenting 
as an echo-lucent area above the parietal pericardium 
was not included in the measurement of epicardial fat. 
Pericardial fat was identified as the hypoechoic space 
anterior to the epicardial fat and parietal pericardium 
(Figure 2). It usually is not deformed substantially 
with cardiac cycles and does not appear hyperechoic. 
 Pericardial  effusion  was delineated as a more 
homogeneous echo-free space with clear visualization 
of both pericardial layers on M-mode 
echocardiography. In contrast, compared with 
pericardial effusion, epicardial fat presented as a 
somewhat inhomogeneous, whitish-speckled, echo-
lucent area. In most patients, we could differentiate 
pericardial effusion from epicardial fat using M-mode 
echocardiography.32 
 
 B-2D  measurements: 
Two-dimensional transthoracic echocardiography was 
performed with a VIVID 3 (GE, 2.5 MHz transducer, 
USA) instrument according to standard techniques, 
with subjects in the left lateral decubitus position. 
Echocardiographic 
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Figure 1. Echocardiographic epicardial fat thickness. Epicardial fat thickness (within red dashed shape) is identified as the echo-
free space between the outer wall of the myocardium and the visceral layer of pericardium in the parasternal long-axis view. 
Epicardial fat thickness is measured during end-systole at the point on the free wall of the right ventricle along the midline 
of the ultrasound beam, with the best effort to be perpendicular to the aortic annulus, used as an anatomic landmark. 
 
 
Figure 2. Epicardial versus pericardial fat thickness. Pericardial fat (within yellow arrows and yellow dashed shape) can be 
identified as the hypoechoic space anterior to the epicardial fat (within red arrows and red dashed shape). Pericardial fat usually 
does not deform substantially with cardiac cycles and does not appear as hyperechoic space. Modified parasternal long-axis 
view. 
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images were recorded in a computer database. The 
off-line measurement of epicardial adipose tissue was 
performed by an echocardiographer who was 
unaware of clinical and angiographic data. 
  Echocardiographically, epicardial fat is identified as 
the relatively echo-free space between the outer wall of 
the myocardium and the visceral layer of pericardium. 
Its thickness is measured perpendicularly on the free 
wall of the right ventricle at end-systole in 3 cardiac 
cycles (Figure 1), according to the criteria of the 
American Society of Echocardiography.33 The 
measurement of EFT on the RV free wall was 
suggested in previous studies because this area has the 
maximum absolute thickness of epicardial fat and these 
two views allow optimum curser-beam orientation.34 A 
normal upper-limit value for EFT has not been 
established yet. Echocardiographic EFT ranges from a 
minimum of 1mm to a maximum of almost 23mm.30 
  Because epicardial fat is compressed during 
diastole, EFT is best measured at end-systole at the 
point on the free wall of the right ventricle at which 
the ultrasound beam is oriented in a perpendicular 
manner, using the aortic annulus as an anatomic 
landmark.29 Maximum EFT is measured from 2D 
parasternal long-axis images at the point on the free wall 
of the right ventricle along the midline of the 
ultrasound beam, perpendicular to the aortic annulus, 
used as an anatomic landmark for this view. 
 For  midventricular  parasternal short-axis assessment, 
maximum EFT is measured from 2D images on the 
right ventricular free wall along the midline of the 
ultrasound beam perpendicular to the interventricular 
septum at midchordal and tip of the papillary muscle 
level, as the anatomic landmarks. The average value of 
3 cardiac cycles from each echocardiographic view was 
determined. The average value of two images 
(parasternal long-axis and short-axis views) was 
obtained and used as the EFT of each patient for 
statistical analysis.  
  The echocardiographically measurable amount of 
epicardial fat was defined as adipose tissue   
thickness > 1mm in at least one echocardiographic 
view. In our echo laboratory, the intra-observer 
correlation coefficient of EFT measurement were 0.92, 
and intra-observer variability of EFT measurement 
yielded differences in repeated measurements that was 
very low (0.5 + 0.3 mm), indicating good 
reproducibility and reliability. Concordance of long-axis 
and short-axis average EFT measurement was also 
excellent at 0.96 (95% confidence interval, 0.96-0.97). 
 
Statistical analyses 
SPSS version 18.0 (SPSS Inc., Chicago, Illinois, USA) 
was used for statistical analysis. All continuous 
variables were expressed as mean ± standard deviation; 
categorical variables were expressed as number and 
percentage. To determine the associations, 
independent sample t-test and chi-square test were 
used. To remove the possible confounding factors, 
multiple linear regression (MLR) test was used. A   
P-value < 0.05 indicated statistical significance. 
Results 
In this study, 117 patients with mean age of   
57.6 ± 9.6 years were enrolled. The youngest patient 
was 36 years old and the oldest was 75 years old. 
Seventy-one of the study subjects (60.7%) were males. 
There was no statistically significant difference in 
terms of demographic variables such as age, sex, BMI, 
smoking status, blood pressure and diabetes between 
two groups (Table 1).  
 
Table 1. Baseline characteristics 
Demographic data  Group P-value
* 
Control (n=52) Case (n=65) 
Age (year)  57.8 ± 9.7  57.4 ± 9.7  0.8 
Sex (male) 29  (55.8) 42 (64.6) 0.4
BMI (Kg/m2)  27.4 ± 2.5  27.7 ± 2.6  0.5 
Smoking 9  (17.3) 10 (15.4) 0.6
Hypertension 14  (26.9) 24 (36.9) 0.3
Diabetes mellitus  5 (9.6) 12(18.5) 0.3
Epicardial fat Thickness (mm) PSLX** 4.4 ± 1.8 4.52 ± 1.9  0.8
Epicardial fat Thickness (mm) PSSX*** 4.73 ± 1.9 4.75 ± 1.9  0.9
Mean epicardial Fat Thickness (mm)  4.58 ± 1.9 4.63 ± 1.9  0.9
Stent diameter (mm)  2.3 ± 0.2 2.9 ± 0.16  0.08
Stent Length (mm)  26.4 ± 5.6 31.3 ± 5.6  < 0.0001
Stented coronary 
vessels 
LAD 1 23 (44.2) 41 (63.1)
0.1  CX 2 15 (28.8) 13 (20)
RCA 3 14 (26.9) 11 (16.9)
Numerical characteristics are presented as mean ± SD and categorical one as number (%) 
* P-values were calculated with student’s t test and chi-square test 
** Parasternal Long Axis view 
*** Parasternal Short Axis view 
LAD stands for left anterior descending artery, CX for circumflex artery and RCA for right coronary artery 
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The results of multiple linear regression test showed 
that even after controlling the possible confounding 
variables, there was no association between ISR and 
epicardial adipose tissue thickness (adjusted   
Beta = 0.039, P = 0.572). 
  Mean EFT ranged from 2.7 through 6.6 mm. As 
indicated in the table 1, EFT (in parasternal short and 
long axis views and mean of thicknesses) was not 
statistically significant between two groups (patients 
with and without ISR). EFT in females and males was 
4.98 ± 1.8 and 4.36 ± 1.8 mm, respectively, which 
although EFT was higher in females but it was not 
statistically significant (P = 0.08). In addition, there 
was no association between age and EFT (r = 0.05,   
P = 0.6) and between BMI and EFT (r = 0.03, P = 0.64). 
There was not any difference for restenosis in major 
coronary vessels (P < 0.1). Stent length statistically 
was higher (P-value< 0.0001) in patients with 
restenosis (case group). 
Discussion 
The main objective of the present study was to assess 
the association between epicardial fat thickness and 
restenosis inside the drug eluting stents (DES) in 
coronary arteries. As far as we know, this was the first 
study to evaluate the potential association between 
sub EFT and re-stenosis of the drug eluting stents. 
Several studies have shown the association between 
echocardiographic EFT and the presence and 
severity of coronary artery disease.27 However, there 
have been no reports of the correlation between 
EFT and restenosis of DES in the coronary arteries. 
Our study demonstrated that there was not any 
association between EFT and restenosis inside the 
drug eluting stent which was deployed in the 
coronary arteries. 
The present study has several limitations. First, the 
study group was highly selected, since it involved only 
limited number of Asian patients pre-selected by 
cardiologist to undergo repeated coronary 
angiography. Second, EFT on the right ventricular 
free wall does not exactly represent the amount of 
total epicardial fat. In some subjects, there is also 
abundant epicardial fat on the left ventricular apex.35 
In addition, as epicardial fat has a 3-dimensional 
distribution, two-dimensional echocardiography may 
not completely assess the total amount of epicardial 
fat. Moreover, the design of our study was cross-
sectional. Further studies which include large number 
of patients are necessary. 
In conclusion, measuring EFT using transthoracic 
echocardiography is simple, feasible and well 
validated. The present study indicated that the EFT 
measured with trans-thoracic echocardiography was 
not correlated with in-stent restenosis in drug eluting 
stents. The echocardiographic measurement of EFT 
may provide additional information for estimating 
restenosis risk and predicting the presence of 
coronary in-stent restenosis. 
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